Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $2000.0.

  • Ultragenyx Pharmaceutical's Cash from Financing Activities fell 9998.21% to $2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $87.0 million, marking a year-over-year decrease of 8802.83%. This contributed to the annual value of $399.2 million for FY2024, which is 285.95% up from last year.
  • Ultragenyx Pharmaceutical's Cash from Financing Activities amounted to $2000.0 in Q3 2025, which was down 9998.21% from $83.6 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Cash from Financing Activities' 5-year high stood at $491.9 million during Q3 2022, with a 5-year trough of -$722000.0 in Q1 2023.
  • Its 5-year average for Cash from Financing Activities is $78.5 million, with a median of $11.2 million in 2024.
  • Data for Ultragenyx Pharmaceutical's Cash from Financing Activities shows a peak YoY increase of 1746695.01% (in 2023) and a maximum YoY decrease of 14478.91% (in 2023) over the last 5 years.
  • Ultragenyx Pharmaceutical's Cash from Financing Activities (Quarter) stood at $85.7 million in 2021, then crashed by 97.8% to $1.9 million in 2022, then soared by 17466.95% to $330.6 million in 2023, then tumbled by 99.04% to $3.2 million in 2024, then crashed by 99.94% to $2000.0 in 2025.
  • Its Cash from Financing Activities was $2000.0 in Q3 2025, compared to $83.6 million in Q2 2025 and $157000.0 in Q1 2025.